$1.6bn Agila injects strengths into Mylan
This article was originally published in Scrip
Executive Summary
Mylan has snapped up Strides Arcolab's injectables arm, Agila Specialties, for $1.6 billion, plus $250 million in additional conditional payments, a transaction, which though seen as expensive, is expected to fast-track Mylan's approach towards becoming a top-three global player in the injectables space.
You may also be interested in...
Strides Exits Australia To ‘Double-Down’ On US Market
Strides founder Arun Kumar says he’s succeeded in putting the company back on the road to health after it shocked financial markets by swinging to a quarterly loss last year. But as part of the recovery plan, the company is selling its key Australia generic business to “double-down” on the US market.
Fosun Pitches for India's Gland
Shanghai Fosun Pharmaceutical Group Co. Ltd. has confirmed it interest in the Indian injectables firm, Gland Pharma Ltd., underscoring how differentiated niche plays continue to attract buyer interest.
India IPR Realities: Pharma, Legal Heads Discuss Winds Of Change, ‘Damocles Sword’
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.